IGC Pharma, Inc. is leveraging AI platforms like MINT-AD for drug discovery, coinciding with the AAIC 2025 conference in Toronto.
3 reports, 1 independent
Updated Jul 8
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
IGC Pharma, Inc. is leveraging AI platforms like MINT-AD for drug discovery, coinciding with the AAIC 2025 conference in Toronto.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- IGC Pharma, Inc. reported an operational bottleneck during engine development while also developing a proprietary enterprise software platform.Sub-event
- IGC Pharma, Inc. is currently developing treatments specifically targeting Alzheimer's dementia.Sub-event
IGC Pharma utilizes AI platforms like MINT-AD for drug discovery during AAIC 2025 in Toronto.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- ACCESS NewswireIGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025 - Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for
- ACCESS NewswireIGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection - Multimodal foundation model enables personalized cognitive forecasts and expands ac